Skip to content
Home/Companies/Diagnostics/ARK Diagnostics

ARK Diagnostics

Diagnostics·US·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns ARK Diagnostics?

ARK Diagnostics is currently owned by ARCHIMED through MED Platform II (2022 vintage), since 2025.

Hand-verified · updated 2026-04-21

ARCHIMED
Investor
ARCHIMED
MED Platform II · 2022 · Buyout

Key facts

HQUnited States
SectorDiagnostics

More from MED Platform II

Other portfolio companies in the same fund.

Esperion Therapeutics
Active
· 2026
Instem
Instem
Active
HealthTechUS· 2023
Symbio
Symbio
Active
PharmaUS· 2023
WiQo
WiQo
Active
HealthTechItaly· 2023
Corealis
Corealis
Active
PharmaCanada· 2022
Natus
Natus
Active
MedTechUS· 2022

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to
Amedes Group
Active
General AtlanticGermany
Appasamy
Appasamy
Active
Warburg PincusIndia
Biocomposites
Biocomposites
Active
TA AssociatesUS
Track ARK Diagnostics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on ARK Diagnostics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue